Clinical Trial

DB-3Q for the Treatment of Medically Refractory Crohn's Disease

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research study is studying DB-3Q as a possible treatment for medically refractory Crohn's disease. The purpose of this study is to research and evaluate safety and effectiveness of the administration of bone marrow mesenchymal stem cell (bmMSC) derived extracellular vesicles product, DB-3Q, the study drug for Crohn's disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-03.
Trial Details
NCT Number NCT07625293
Lead Sponsor Direct Biologics, LLC
Conditions Crohn Disease (CD)
Enrollment 36 participants
Start Date 2026-06
Primary Completion 2027-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-12